Brief Title
Short and Long Term Efficacy of Combined Cabergoline and Octreotide Treatment in Acromegalic Patients
Official Title
Short and Long Term Efficacy of Combined Treatment in Controlling IGI-I Levels in Acromegaly
Brief Summary
In acromegaly, nearly 40% of patients fail to control GH/IGF-I levels with somatostatin analogues (SA). Dopaminergic agonists (DA) are even less effective, but combination therapy with SA and DA normalizes IGF-I levels in 33-56% of patients in short-term studies. This study was designed to evaluate short and long term efficacy of cabergoline in controlling IGF-I levels in acromegalic patients receiving octreotide.
Study Type
Observational
Primary Outcome
Control of IGF-I levels
Secondary Outcome
control IGI-I levels
Condition
Acromegaly
Intervention
cabergoline
Study Arms / Comparison Groups
Responders to cabergoline
Description: patients with active disease under octreotide treatment received addition of increasing doses of cabergoline (1.0, 2.0 and 3.5mg/week)
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Drug
Estimated Enrollment
19
Start Date
May 2005
Completion Date
December 2008
Primary Completion Date
May 2007
Eligibility Criteria
Inclusion Criteria: - Active disease, under octreotide treatment at least 9 months Exclusion Criteria: - Cabergoline allergy
Gender
All
Ages
18 Years - 80 Years
Accepts Healthy Volunteers
No
Contacts
Julio Abucham, PhD, ,
Location Countries
Brazil
Location Countries
Brazil
Administrative Informations
NCT ID
NCT01014793
Organization ID
Mattapr1
Study Sponsor
Federal University of São Paulo
Study Sponsor
Julio Abucham, PhD, Study Director, Federal University of São Paulo
Verification Date
November 2009